Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
January 11, 2022 07:00 ET
|
Inivata
Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program Research Triangle Park, NC, USA and Cambridge, UK, 11 January 2022 -- Inivata, a leader...
Inivata Offers Mobile Phlebotomy Services for patients undergoing InVisionFirst® Lung ctDNA liquid biopsy
May 12, 2020 07:00 ET
|
Inivata
Inivata Offers Mobile Phlebotomy Services for patients undergoing InVisionFirst® Lung ctDNA liquid biopsy Research Triangle Park, NC, USA May 12, 2020 – Inivata (www.inivata.com) a leader in...
Inivata Signs Distribution Agreement with IPS Genomix for InVision® Genomic Tests in the Middle East and Africa
July 16, 2019 07:00 ET
|
Inivata
Inivata Signs Distribution Agreement with IPS Genomix for InVision® Genomic Tests in the Middle East and Africa Research Triangle Park, NC, USA and Cambridge, UK, and Dubai, UAE , July 16, 2019...
Inivata publishes positive clinical validation results and real-world utility for its InVisionFirst®-Lung liquid biopsy test
April 26, 2019 07:00 ET
|
Inivata
Inivata publishes positive clinical validation results and real-world utility for its InVisionFirst®-Lung liquid biopsy test InVisionFirst®-Lung demonstrated excellent concordance with tissue...
Inivata to Present New Clinical Data on the Utility of the InVision® Liquid Biopsy Platform in Advanced Non-Small Cell Lung Cancer (NSCLC) at WCLC 2018
September 10, 2018 07:00 ET
|
Inivata
Inivata to Present New Clinical Data on the Utility of the InVision® Liquid Biopsy Platform in Advanced Non-Small Cell Lung Cancer (NSCLC) at WCLC 2018 Oral presentations and posters to feature...